We defined “intractable asthma” at the 3rd Asia-Pacific Congress on Diseases of the Chest (1973), Symposium [Bronchial Asthma] as follows:
1) Attacks develop easily and frequently with little correlation to provocation and seasonal factors.
2) Attacks respond poorly to treatment and show a tendency to develop status asthmaticus.
3) Steroid dependence is remarkable.
The purpose of this study was to clarify the characteristics of intractable asthma, and then to find rational and effective treatments.
1) Administration of β-stimulants is known to cause remission of bronchospasm by increasing cAMP content in bronchial smooth muscles. However, the effect of β-stimulants is usually weakened by the following factors. 1) aging, 2) occurence of attacks throughout the year, 3) chronic atopic type, 4) complications of chronic sinusitis paranasalis and, 5) chronic pulmonary emphysema, 6) continuous administration of β-stimulants.
2) Repetition of both sensitizations and anaphylactic attacks by allergen inhalations induced a β-blocking condition in the airways. Thus it is reasonable that the effects of catecholamine secreted during both exercise and the attacks are diminished in asthmatic patients. Therefore this β-blocking mechanism has been recognized as one of the new factors causing intractable asthma.
3) We examined the effect of airway narrowing and impairment of mucociliary transport on mucous plug formation in airways using chicken tracheas. It was found that mucous plug formation was accelerated by airway narrowing, excessive volume of mucous and ciliary dysfunction. It was also observed that once a mucous plug was formed, it was often retained even when airway narrowing was almost completely relieved.
4) Using frog palates, we studied the effects of pharmacologic agents on mucociliary transport and mucous production. Since isoproterenol increased mucous production to the same degree as acetylcholine, isoproterenol, an effective β-stimulant, might form mucus plugs when slight narrowing of airways remains.
5) A series of studies suggested that the β-blocking condition in the airway is involved in the development of intractable asthma. Therefore, unlike Ca-antagonists, the application of forskolin, a direct activator of adenylate cyclase, and cGMP-related substances such as nitroprusside and 8Br-cGMP are hopeful new treatments for intractable asthma.
View full abstract